Aurobindo Pharma Share News - Latest Updates, Live News & More

More news about Aurobindo Pharma

Aurobindo Pharma acquires 26% stake in Swarnaakshu Solar for Rs 52 lakhs

Aurobindo Pharma has completed the acquisition of a 26% equity stake in Swarnaakshu Solar Power Private Limited with an initial investment of Rs 52 lakhs. The company executed a solar power purchase agreement to procure power for captive consumption, aligning with the Government of Telangana's captive power policy. The total approved investment is Rs 10.40 crores, with the balance to be disbursed based on project progress.

23Jun 26

Aurobindo Pharma USA gets FTC nod for $250m Lannett buy

Aurobindo Pharma USA Inc received approval from the U.S. Federal Trade Commission to acquire Lannett Company LLC for $250 million on a cash-free, debt-free basis. The transaction, expected to close by June 2026, includes a manufacturing facility in Seymour, Indiana with a capacity of 4 billion doses annually. The acquisition is anticipated to be immediately accretive to earnings and generate cost efficiencies.

22Jun 26

Bernstein, HSBC Weigh In on Aurobindo Pharma Amid FDA OAI Classification

Aurobindo Pharma's Eugia Unit-III has received a US FDA OAI classification following an inspection with 11 findings. Bernstein maintains a Market Perform rating with a TP of ₹1,498, warning of ~35 frozen ANDAs and a 3–3.5% FY27 EPS drag. HSBC retains a Buy rating with a TP of ₹1,580, highlighting the Lannett acquisition as a driver toward USD 2 billion in US sales by FY27, with gAdvair launch and Pen G and China plant cost breakeven as additional catalysts.

20Jun 26

Aurobindo Pharma promoters disclose no new encumbrances as of March 31, 2026

Aurobindo Pharma Limited confirmed in a regulatory filing that its promoters have not created any new encumbrances on their shares as of March 31, 2026, aside from those previously disclosed. The declaration, made by K. Nithyananda Reddy on behalf of the promoter group, adheres to SEBI regulations regarding substantial acquisition of shares. The filing details the promoter group's total holding of 30,09,48,721 shares, which constitutes 51.82% of the company's total share capital.

10Jun 26

Aurobindo Pharma to attend Goldman Sachs investor meet

Aurobindo Pharma Limited officials will participate in a group investor meeting organized by Goldman Sachs on June 12, 2026, in Hyderabad. The meeting, part of the Goldman Sachs CRO/CDMO Tour, is scheduled from 03:30 PM to 05:00 PM IST. The company stated that no unpublished price sensitive information (UPSI) will be discussed during the interactions, though the schedule remains subject to change.

06Jun 26

Aurobindo Pharma officials to attend UBS virtual investor meet

Aurobindo Pharma Limited announced that its officials will participate in the UBS - Virtual Generics and Biosimilar Day, a virtual investor meeting scheduled for June 10, 2026, from 19:00 to 20:00 IST. The company confirmed that no unpublished price sensitive information will be discussed during the event. The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited on June 5, 2026, by B. Adi Reddy, Company Secretary.

05Jun 26

Aurobindo Pharma Receives Final US FDA Approval for Tofacitinib Tablets in 5 mg and 10 mg Strengths

Aurobindo Pharma has received final US FDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths, marking a key regulatory milestone. The approval underscores the company's commitment to FDA quality standards and further strengthens its generics pipeline for the US market.

04Jun 26

Aurobindo Pharma Inaugurates TheraNym Biologics Facility With MSD as Anchor Customer

Aurobindo Pharma launched TheraNym, one of India's largest dedicated biologics CMO facilities, in Borapatla, Telangana on June 3, 2026, with MSD as anchor customer. The facility features 15 KL bioreactors, advanced downstream processing, aseptic fill-finish, and quality control labs, marking the company's strategic entry into biologics contract manufacturing to serve global pharma supply chains.

04Jun 26

Aurobindo Pharma to attend ICICI Securities conference on June 8

Aurobindo Pharma Limited officials will participate in the ICICI Securities India Investor Conference on June 8, 2026, in Mumbai. The meeting, scheduled from 10:00 to 18:00 IST, involves in-person and group interactions with investors. The company confirmed that no unpublished price sensitive information will be discussed during the event.

28May 26

Aurobindo Pharma attends BofA 2026 India Conference on June 2

Aurobindo Pharma Limited announced its participation in the BofA 2026 India Conference scheduled for June 2, 2026, in Mumbai. Company officials will conduct in-person and group meetings between 09:00 AM and 06:00 PM IST. The company confirmed that no unpublished price sensitive information will be disclosed during these interactions.

28May 26

Aurobindo Pharma to attend Investec US Pharma meeting on June 4

Aurobindo Pharma officials will attend the Investec US Pharma and Healthcare Bus Tour 7.0 in New Jersey on June 4, 2026, to update investors on operations. The company confirmed no unpublished price sensitive information will be shared during the meeting.

25May 26

US FDA Classifies Aurobindo Unit as OAI

Aurobindo Pharma Limited disclosed that the US FDA classified Unit-I of its subsidiary Eugia Pharma Specialities Limited as OAI following an inspection from February 16 to February 27, 2026. The inspection resulted in four observations, with the formal communication received on May 23, 2026. The company confirmed that there is no impact on its financials or operations due to this action.

25May 26

Aurobindo Pharma Draws Mixed Analyst Views; DAM Capital, Goldman Sachs, Nuvama Maintain Buy

Aurobindo Pharma has received Buy ratings from DAM Capital (₹1767), Goldman Sachs (₹1550), Nuvama (₹1680), and BofA Securities (₹1700), with brokerages citing the Lannett deal, Pen-G ramp-up, Europe growth, and biosimilar investments as key drivers. CLSA, however, downgraded the stock to Hold at ₹1490, flagging higher opex and margin pressure, with meaningful growth expected only from FY28 onwards.

23May 26

Aurobindo Pharma Unit Launches French Subsidiary

Aurobindo Pharma Limited announced that its wholly owned step-down subsidiary, Agile Pharma BV, has incorporated a new entity in France named Arrow Pharma Production SAS. The new subsidiary, established on May 21, 2026, will focus on the manufacturing of generic formulations. The authorized capital of the entity is 100,000 EUR, divided into 100,000 shares of 1 EUR each, fully owned by Agile Pharma BV.

23May 26

Aurobindo Pharma FY26 Net Profit Rises to ₹3,503 Cr

Aurobindo Pharma announced its audited financial results for the quarter and year ended March 31, 2026, reporting a consolidated net profit of ₹3,503 crore for FY26, a slight increase from the previous year. Revenue grew by 6.1% annually to ₹33,653 crore, while Q4 revenue rose 5.6% to ₹8,853 crore. The company published these results in newspapers on May 23, 2026, and has guided for EBITDA margins above 21% in FY27, driven by improved operational efficiency.

22May 26

Aurobindo Pharma Appoints RPR & Associates as Secretarial Auditor

Aurobindo Pharma Limited has accepted the resignation of M/s. MRR & Associates as Secretarial Auditor effective May 22, 2026, due to health issues. The board has appointed M/s. RPR & Associates as the new Secretarial Auditors for a term of five consecutive years from FY 2026-27 to FY 2030-31, pending shareholder approval.

19May 26

Aurobindo Pharma Extinguishes 54,23,728 Equity Shares Under ₹800 Crore Buyback Programme

Aurobindo Pharma Limited extinguished 54,23,728 equity shares on May 14, 2026, under its tender offer buyback conducted at ₹1,475 per share for an aggregate amount not exceeding ₹800,00,00,000. All extinguished shares were in dematerialised form, with confirmations received from both NSDL and CDSL. The company's paid-up share capital has been reduced from 58,08,01,623 equity shares to 57,53,77,895 equity shares of ₹1/- each following the extinguishment. The process was carried out in compliance with the SEBI (Buy-Back of Securities) Regulations, 2018.

18May 26

Telangana High Court Dismisses Aurobindo Pharma Promoters' Writ Petition Against SEBI's Profit Deposit Directive

The Telangana High Court dismissed a writ petition filed by Aurobindo Pharma's promoter group members — Mr. P. V. Ramprasad Reddy, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited — challenging SEBI's October 2020 directive to deposit Rs. 6.53 crores in trading profits along with 12% per annum interest into the Investor Protection and Education Fund. The order, dated May 6, 2026, has no impact on Aurobindo Pharma's financials or operations, and the petitioners are evaluating further legal options.

16May 26

Aurobindo Pharma Subsidiary CuraTeQ Biologics Secures CDSCO Marketing Authorisation for Bevqolva® Bevacizumab Biosimilar

Aurobindo Pharma's subsidiary CuraTeQ Biologics has received CDSCO marketing authorisation (Form CT 23) for Bevqolva®, a bevacizumab biosimilar. This approval enables CuraTeQ Biologics to market the biosimilar product in India. The development marks a notable regulatory achievement for Aurobindo Pharma's biologics arm, reinforcing its presence in the oncology biosimilars space.

14May 26

Aurobindo Pharma Schedules Q4FY26 Board Meeting on May 21 and Earnings Call on May 22

Aurobindo Pharma has scheduled a Board of Directors meeting on May 21, 2026 to approve standalone and consolidated audited financial results for Q4 and FY26, followed by an Analyst/Investor Earnings Call on May 22, 2026 at 8:30 AM IST via Zoom. The Trading Window, closed since April 1, 2026, will reopen on May 24, 2026 after the customary 48-hour period post results declaration.

13May 26

Aurobindo Pharma Records ₹30.08 Crore Block Trade on NSE at ₹1,496.50 Per Share

Aurobindo Pharma witnessed a block trade on the NSE involving approximately 2,00,977 shares executed at ₹1,496.50 per share, with the aggregate deal value amounting to ₹30.08 crores. Such large-scale block trades are typically associated with institutional investors and may indicate portfolio rebalancing or strategic position changes by major market participants.

08May 26

Aurobindo Pharma Completes Buyback of 54,23,728 Equity Shares at ₹1,475 Per Share for ₹800 Crore

Aurobindo Pharma Limited has completed its buyback of 54,23,728 equity shares at ₹1,475 per share, utilizing ₹799,99,98,800 (excluding transaction costs) out of the maximum buyback size of ₹800,00,00,000. The buyback, conducted via the tender offer route, was oversubscribed approximately 5.43 times, with KFin Technologies Limited recording 26,568 valid bids for 2,94,73,022 equity shares. Settlement was completed by Indian Clearing Corporation Limited on May 7, 2026, with the extinguishment of accepted shares expected on or before May 18, 2026. Post-buyback, the company's issued and paid-up share capital stands at 57,53,77,895 equity shares, subject to formal extinguishment.

07May 26

Aurobindo Pharma Unit-VII Receives US FDA Voluntary Action Indicated Classification

Aurobindo Pharma Limited's Unit-VII oral solid dosage manufacturing facility in Telangana has received a Voluntary Action Indicated (VAI) classification from the US FDA, following an inspection conducted from January 28 to February 10, 2026, which issued 9 Form 483 observations. The FDA has formally closed the inspection, and the development was disclosed under SEBI Regulation 30 by Company Secretary B. Adi Reddy on May 6, 2026.

05May 26

Aurobindo Pharma Intimates Resignation of Dr. Sanjay Chaturvedi as CEO of Subsidiary Apitoria Pharma

Aurobindo Pharma Limited has disclosed the resignation of Dr. Sanjay Chaturvedi as Chief Executive Officer of Apitoria Pharma Private Limited, its wholly owned subsidiary, effective May 4, 2026. Dr. Chaturvedi cited his intention to pursue a different opportunity as the reason for stepping down. The intimation was filed with both NSE and BSE in compliance with Regulation 30, and was signed by Company Secretary B. Adi Reddy.

02May 26

Aurobindo Pharma's CuraTeQ Biologics Receives Health Canada NOC for Bevqolva

Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics has received Notice of Compliance from Health Canada for its bevacizumab biosimilar Bevqolva™, announced on May 1, 2026. The product, available in 100 mg and 400 mg formulations, treats multiple cancers including colorectal and lung by inhibiting angiogenesis. CuraTeQ previously launched Bevqolva™ commercially in the UK in 2025 and has the product under EMA review for European market access.

30Apr 26

Aurobindo Pharma Announces Retirement of Chief Business Officer, Emerging Markets

Aurobindo Pharma has disclosed the retirement of Mr. N. Ravi Kiran, Chief Business Officer, Emerging Markets, effective from the close of business hours on April 30, 2026. The announcement was made pursuant to Regulation 30 of the SEBI Listing Regulations. The company has provided the required details in an annexure to the disclosure.

23Apr 26

Aurobindo Pharma Receives USFDA Approval for Glycerol Phenylbutyrate Drug

Aurobindo Pharma has secured USFDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per ml, targeting a US$ 50.2 million market opportunity. The product, manufactured at Unit-III facility, treats urea cycle disorders and expands the company's ANDA portfolio to 579 total approvals.

23Apr 26

Aurobindo Pharma Buyback Opens at ₹1,475 Per Share for Up to 54,23,728 Equity Shares

Aurobindo Pharma Limited has commenced its buyback offer for up to 54,23,728 equity shares at ₹1,475 per share, aggregating to ₹800,00,00,000. The offer opened on April 23, 2026, and closes on April 29, 2026. Eligible shareholders include small shareholders with an entitlement of 7 equity shares out of every 61 held, and general category shareholders entitled to 2 equity shares out of every 249 held as on the record date of April 17, 2026. The letter of offer was dispatched electronically on April 21, 2026. Shareholders can check their entitlement through the registrar's website. Axis Capital Limited serves as the manager to the offer, while KFin Technologies Limited is the registrar.

21Apr 26

Aurobindo Pharma Records Rs. 33.11 Crore Block Trade on NSE

Aurobindo Pharma Ltd. executed a significant block trade on NSE involving 241,320 shares at Rs. 1371.90 per share, totaling Rs. 33.11 crores. The transaction represents substantial institutional trading activity in the pharmaceutical company's stock, indicating strong investor interest and potential portfolio adjustments by large market participants.

20Apr 26

Aurobindo Pharma Gets USFDA Approval for Extended-Release Cough Suspension

Aurobindo Pharma has secured USFDA approval for its extended-release dextromethorphan polistirex oral suspension, targeting a US$ 138.00 million cough medication market. The OTC product will be manufactured at APL Healthcare's Unit-IV facility and is scheduled for launch in Q2FY27, marking the company's 580th ANDA approval from the USFDA.

16Apr 26

Macquarie Maintains Underperform Rating on Aurobindo Pharma Despite TheraNym's Expanded Merck Deal

Macquarie has maintained its Underperform rating on Aurobindo Pharma with a target price of ₹1,050, despite TheraNym Biologics' expanded partnership with Merck involving a $150-175 million greenfield facility with 60,000L bioreactor capacity. While the deal validates biologics capabilities, analysts expect meaningful financial benefits only in 3-4 years.

09Apr 26

Aurobindo Pharma Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026

Aurobindo Pharma Limited filed its mandatory SEBI compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026, on April 9, 2026. The certificate confirms proper reporting of dematerialized and rematerialized securities to all relevant stock exchanges. Supporting documentation was provided by KFin Technologies Limited, the company's Registrar and Transfer Agent, with certificates dated April 1, 2026.

08Apr 26

Aurobindo Pharma Publishes Detailed ₹800 Crore Share Buyback Announcement

Aurobindo Pharma has released detailed regulatory documentation for its ₹800 crore share buyback program, covering 54.23 lakh shares at ₹1,475 each. The announcement provides extensive implementation details, regulatory compliance confirmations, and outlines the tender offer process through BSE with special provisions for small shareholders.

08Apr 26

Aurobindo Pharma Gets USFDA Final Approval For Dapagliflozin Tablets Generic

Aurobindo Pharma has received USFDA final approval for its Dapagliflozin Tablets in 5mg and 10mg strengths, serving as a generic equivalent to AstraZeneca's Farxiga. The company secured 180 days of shared generic drug exclusivity by being among the first ANDA applicants with paragraph IV certification. This approval targets a substantial US$ 10.2 billion diabetes treatment market and brings the company's total ANDA approvals to 579, including 554 final approvals and 25 tentative approvals.

08Apr 26

Aurobindo Pharma Receives USFDA Approval for Diabetes Drug with 180-Day Market Exclusivity

Aurobindo Pharma Limited received USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in four strengths, with an estimated market size of US$ 514 million. The company secured 180 days of shared generic drug exclusivity as one of the first ANDA applicants with paragraph IV certification. Products will be manufactured at Unit-IV of APL Healthcare Limited and launched immediately, adding to the company's portfolio of 579 ANDA approvals from USFDA.

07Apr 26

Aurobindo's CuraTeQ Biologics Reports Positive Phase 3 Results for Omalizumab Biosimilar

Aurobindo Pharma's subsidiary CuraTeQ Biologics achieved positive Phase 3 results for its omalizumab biosimilar BP11, demonstrating high comparability to reference product Xolair in a 608-patient trial across multiple countries. The study met all primary endpoints with confidence intervals within predefined margins, supporting regulatory submissions to EMA and FDA planned by end of Q2 2026 for chronic spontaneous urticaria, allergic asthma, and chronic rhinosinusitis indications.

06Apr 26

Aurobindo Pharma Approves ₹800 Crore Share Buyback at ₹1,475 Per Share

Aurobindo Pharma's board has approved a comprehensive share buyback program worth ₹800.00 crores, involving repurchase of up to 54,23,728 equity shares at ₹1,475.00 per share through tender offer route. The buyback represents 0.93% of total paid-up equity capital with record date scheduled for April 17, 2026, conducted under SEBI regulations with current promoter shareholding at 51.82%.

06Apr 26

Aurobindo Pharma Board Approves Transfer of Domestic Branded Generic Business to Subsidiary

Aurobindo Pharma Limited's board approved the transfer of its domestic branded generic pharmaceutical formulations business to wholly owned subsidiary Auropharm Limited for INR 143.21 crores on April 6, 2026. The business contributed Rs. 1,753.40 million in turnover (0.55% of consolidated turnover) and will be transferred as a slump sale on going concern basis. The strategic move aims to consolidate domestic pharmaceutical operations under the subsidiary for enhanced operational efficiency, with completion expected within 90 to 120 days.

31Mar 26

Aurobindo Pharma Extends Solar Acquisition Timeline to June 2026

Aurobindo Pharma has extended its timeline for completing the acquisition of up to 26% stake in Swarnaakshu Solar Power Private Limited to June 30, 2026, due to pending state government approval for the captive solar power plant project. The company has been regularly updating stock exchanges about this strategic renewable energy investment since February 2025.

30Mar 26

Aurobindo Pharma Shareholders Approve Independent Director Appointment with 98.96% Majority

Aurobindo Pharma Limited successfully concluded its postal ballot process with shareholders approving Dr. Punita Kumar Sinha's appointment as Independent Director with 98.96% majority. The remote e-voting process from February 27 to March 28, 2026, saw 88.40% voter turnout with 513,445,001 votes polled out of 580,801,623 total shares. Dr. Sinha will serve as Independent Director for three years from February 9, 2026 to February 8, 2029, not liable to retire by rotation.

27Mar 26

Aurobindo Pharma Subsidiary CuraTeQ Biologics Partners with STADA for EU Markets

Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics has formed a strategic partnership with STADA Arzneimittel AG for marketing and distribution of two EMA-approved biosimilars in key European markets including France and Germany. The agreement enables CuraTeQ to leverage STADA's established distribution network while creating new brand names for each biosimilar to optimize market positioning in the respective territories.

25Mar 26

UBS Raises Aurobindo Pharma Target Price to Rs 1400 Amid Balanced Risk-Reward Outlook

UBS has raised Aurobindo Pharma's target price to Rs 1400 from Rs 1200 while maintaining a neutral rating, citing balanced risk-reward dynamics. The brokerage noted the company's moderated US base business and gradual diversification strategy, including the inspection of Eugia III facility. However, UBS expects meaningful contribution from diversification efforts only from FY28-29, supporting their cautious outlook despite the price target increase.